The Effect of Pre-operative Use of Finasteride Versus Cyproterone Acetate on Blood Loss With Transurethral Resection of Prostate

The Effect of Short Term Use of Finasteride Versus Cyproterone Acetate on Perioperative Blood Loss With Mono Polar Transurethral Resection of Prostate

Status

Completed

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04848181

Enrollment

Registered

2021-04-19

Start date

2019-07-01

Completion date

2020-07-09

Last updated

2021-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Hyperplasia

Brief summary

Perioperative bleeding is the most common complication related to transurethral resection of prostate, the aim of the study is to compare the effect of pre-operative use of finasteride versus Cyproterone acetate on blood loss with mono polar TURP

Detailed description

This prospective randomized controlled study to compare the effect of pre-operative use of finasteride versus Cyproterone acetate on blood loss with mono polar TURP

Interventions

DRUGcyproterone acetate

two weeks Cyproterone acetate administration before TURP

DRUGfinasteride

two weeks finasteride administration before TURP

DRUGno treatment received

no treatment received before TURP

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

MALE

Healthy volunteers

Yes

Inclusion criteria

* Patients with benign prostatic hyperplasia with prostate size (60-100) grams * Lower urinary tract symptoms (LUTS) not responding to medical treatment * Recurrent prostatic bleeding * Recurrent acute urinary retention * Chronic urinary retention

Exclusion criteria

* Patients with coagulation disorders * Previous prostatic surgery * Previous finasteride administration * Bladder pathology (urinary bladder stones - bladder mass) * Suspected or proved cancer prostate * Hepatic or renal impairment * Patients unfit for operation eg. Decompensated heart failure, poor chest condition

Design outcomes

Primary

Measure	Time frame	Description
intraoperative blood loss	immediately after surgery	assessment of intraoperative blood loss during TURP
post operative Hb	24 hour post operative	measuring serum haemoglobin level at first post operative
post operative Hcv	24 hour post operative	measuring serum haematocrit value at first post operative
operative duration	immediately after surgery	assessment of the duration of the operation
microvascular density(MVD)	2 weeks after drug intake	assesment of MVD of the prostate by histological examination using high power field microscope

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026